Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Oncolytics Biotech (NASDAQ: ONCY) has scheduled a conference call and webcast for March 3, 2022, at 5:00 p.m. ET to review its fourth quarter and full year 2021 financial results. The company is advancing pelareorep, an immunotherapeutic agent aimed at treating various cancers by inducing anti-cancer immune responses. Ongoing and planned clinical trials are underway, including studies evaluating pelareorep in combination with checkpoint inhibitors. The investor relations page will host the webcast, available for three months.
- Ongoing clinical trials for pelareorep could enhance growth potential.
- Potential synergies with checkpoint inhibitors may improve treatment efficacy.
- Forward-looking statements imply risks related to clinical trial outcomes and regulatory challenges.
- COVID-19 could disrupt ongoing projects and clinical trial timelines.
SAN DIEGO, Calif. and CALGARY, AB, Feb. 22, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, March 3, 2022, at 5:00 p.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2021.
Conference Call & Webcast
Date: Thursday, March 3, 2022
Time: 5:00 p.m. Eastern Standard Time
Dial In – North American Toll-Free: (888) 664-6383
Dial In – International: (416) 764-8650
Conference ID (if needed): 4650-7590
Webcast: please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial in replay will be available for one week and can be accessed by dialing (888) 390-0541 (North America) or (416) 764-8677 (International) and using replay code: 507-590#.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the mode of action and potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' plans to advance towards a registration study in metastatic breast cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Company Contact Jon Patton Director of IR & Communication +1-858-886-7813 | Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +1-917-679-9282 |
Logo - https://mma.prnewswire.com/media/1064079/Oncolytics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-301486117.html
SOURCE Oncolytics Biotech® Inc.
FAQ
When will Oncolytics Biotech discuss its financial results?
What is the focus of the conference call hosted by Oncolytics Biotech?
What is pelareorep and its significance for Oncolytics Biotech?
How can investors access the Oncolytics Biotech conference call?
What potential challenges does Oncolytics Biotech face with its clinical trials?
